Insights

Gathering insights about GDT…

Similar companies to GDT

GDT Tech Stack

GDT uses 8 technology products and services including Fusion Ads, WordPress, Lightbox, and more. Explore GDT's tech stack below.

Fusion Ads
Advertising
WordPress
Content Management System
Lightbox
Javascript Libraries
jQuery Modal
Javascript Libraries
Choices
Javascript Libraries
Revslider
Miscellaneous
The Events Calendar
Web Platform Extensions
Apache
Web Servers

Media & News

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers
Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology Another Patent Granted for CytoMed's Allogeneic Induced Pluripotent Stem Cell (“iPSC”)-derived Hybrid Gamma Delta Natural Killer T (γδ NKT) cells technology
Jul 17, 2024 | www.globenewswire.com
CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration
SINGAPORE / ACCESSWIRE / March 20, 2024 / CytoMed Therapeutics Limited (NASDAQ:GDTC) ("CytoMed" or "the Company"), a Singapore biopharmaceutical company that focuses on utilizing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for treating a range of cancers, recently announced that it has entered into a research collaboration agreement with Sengkang General Hospital Pte Ltd., a public hospital in Singapore and a member of the SingHealth Group.
Mar 20, 2024 | www.accesswire.com
CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies
SINGAPORE, March 18, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, has obtained board approval to launch, subject to certain terms and conditions, a pilot program (“Program”) to isolate and cryo-store peripheral blood mononuclear cells (“PBMCs”) for and as a reward to loyal shareholders of CytoMed on a complimentary basis. This Program is in line with the Company's strategy to build up a private bank of PBMC donors to develop allogeneic off-the-shelf cellular therapies using pre-qualified healthy donor blood. This Program will commence on June 1, 2024, or at such other date as CytoMed shall provide. Interested shareholders are advised to refer to CytoMed's website for any future updates regarding the Program.
Mar 18, 2024 | www.globenewswire.com
CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair
SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement (“RCA”) with Sengkang General Hospital Pte Ltd (“SKH”), a public hospital in Singapore and a member of the SingHealth group to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (“UC-MSCs”) to treat cartilage injury. This injectable therapy will be implemented in vivo to support the application and commencement of a proposed Phase 1 clinical trial in Singapore, and is anticipated to complete within two years.
Mar 04, 2024 | www.globenewswire.com
Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology
The Company now has exclusive rights to a Malaysia, US and China patent The Company now has exclusive rights to a Malaysia, US and China patent
Jan 29, 2024 | www.globenewswire.com
CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology
SINGAPORE , Dec. 5, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced that it has entered into a Heads of Agreement (HOA) with CytoMed Therapeutics China Limited (CytoMed China), a company incorporated in Hong Kong and a Memorandum of Understanding (MOU) with BioNex Solutions Inc., 千尋生命科學. The HOA forms a collaborative effort between CytoMed and CytoMed China to explore and investigate the safety, tolerability, potency, and efficacy of CytoMed's proprietary allogeneic gamma delta T cells for the treatment of various cancers (including solid tumors) in human subjects through an investigator-initiated trial (IIT) in the People's Republic of China (China).
Dec 05, 2023 | www.prnewswire.com
CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update
Conference call webcast is scheduled for November 22 at 9 a.m. ET. SINGAPORE , Nov. 17, 2023 /PRNewswire/ -- CytoMed Therapeutics Limited (NASDAQ: GDTC) ("CytoMed" or "Company"), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of various cancers, today announced its first half of 2023 financial results and provided clinical and corporate updates.
Nov 17, 2023 | www.prnewswire.com

GDT's Email Address Formats

GDT uses at least 2 format(s):

GDT Email Formats	Example	Percentage
First.Last@gdt.com	John.Doe@gdt.com	61%
FLast@gdt.com	JDoe@gdt.com	18%
FirstLast@gdt.com	JohnDoe@gdt.com	4%
First@gdt.com	John@gdt.com	1%
Last.First@gdt.com	Doe.John@gdt.com	1%
FirstL@gdt.com	JohnD@gdt.com	1%
Last.F@gdt.com	Doe.J@gdt.com	1%
Last_First@gdt.com	Doe_John@gdt.com	1%
F.Last@gdt.com	J.Doe@gdt.com	1%
FirLast@gdt.com	JohDoe@gdt.com	1%
FirstLa@gdt.com	JohnDo@gdt.com	1%
LastFirst@gdt.com	DoeJohn@gdt.com	1%
FirstLas@gdt.com	JohnDoe@gdt.com	1%
First.L@gdt.com	John.D@gdt.com	1%
F_Last@gdt.com	J_Doe@gdt.com	1%
LastFir@gdt.com	DoeJoh@gdt.com	1%
LastF@gdt.com	DoeJ@gdt.com	1%
First_Last@gdt.com	John_Doe@gdt.com	1%
F-Last@gdt.com	J-Doe@gdt.com	1%
LastFi@gdt.com	DoeJo@gdt.com	1%

Frequently Asked Questions

What is GDT's stock symbol?

GDT is a publicly traded company; the company's stock symbol is GDTC.

What is GDT's official website and social media links?

GDT's official website is gdt-rio.com.br and has social profiles on LinkedIn.

What is GDT's NAICS code?

GDT's NAICS code is 3391 - Medical Equipment and Supplies Manufacturing.

How many employees does GDT have currently?

As of November 2021, GDT has approximately 270 employees across 6 continents, including AsiaNorth AmericaEurope. Key team members include Chief Executive Officer: B. G.Vice President And Occupational Therapist: L. T.Head Coach Gdt Slough And Uxbridge Ltc: G. N.. Explore GDT's employee directory with LeadIQ.

What industry does GDT belong to?

GDT operates in the Medical Equipment Manufacturing industry.

What technology does GDT use?

GDT's tech stack includes Fusion AdsWordPressLightboxjQuery ModalChoicesRevsliderThe Events CalendarApache.

What is GDT's email format?

GDT's email format typically follows the pattern of . Find more GDT email formats with LeadIQ.

GDT

Medical Equipment Manufacturing201-500 Employees

Learn about working at GDT. Join LinkedIn today for free. See who you know at GDT, leverage your professional network, and get hired.

Company Overview

Website: gdt-rio.com.br
Stock Symbol: GDTC
NAICS Code: 3391 - Medical Equipment and Supplies Manufacturing
Employees: 201-500

Media & News

Funding & Financials

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to GDT

Centric

EDP

TELADATA

GDT Tech Stack

Media & News

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

Malaysian Patent Granted for CytoMed Therapeutics' Licensed Allogeneic CAR-Gamma Delta T Cell Technology

CytoMed Therapeutics Signs HOA and MOU to Advance Research on Allogeneic Gamma Delta T Cell Technology

CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update

GDT's Email Address Formats

Frequently Asked Questions

What is GDT's stock symbol?

What is GDT's official website and social media links?

What is GDT's NAICS code?

How many employees does GDT have currently?

What industry does GDT belong to?

What technology does GDT use?

What is GDT's email format?

GDT

Company Overview

Media & News

CytoMed Therapeutics Acquires Cord Blood Banking Licence and Assets to Entrench Its Strategy in Allogeneic, Off-the-shelf Donor-derived Gamma Delta (γδ) T Cells Technology for Solid and Liquid Cancers

CytoMed Diversifies into Regenerative Medicine after Research Collaboration with Singapore's Sengkang General Hospital to Test Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Regeneration

CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?